Short-Term Debt to Capital: Amarin Corporation plc (AMRN)

Amarin Corporation plc (AMRN) is developing a unique cardiological ecosystem where the drug Vascepa has become a fundamental tool for the prevention of cardiac pathologies. Business growth relies on the integration of this agent into global practice and the optimization of internal costs supported by liquid reserves. The current indicator is 0.00, and stable product output is ensured by certified partner facilities, as clearly demonstrated by this price chart.

Investors must evaluate the financial stability of Amarin Corporation plc (AMRN) by analyzing its liability structure. This metric measures the proportion of loans maturing within one year relative to equity, determining liquidity risk during external shocks. The trend in the short-term debt-to-equity ratio demonstrates the balance between aggressive growth and viability. For a cardiology brand leader, such stability is critical when supporting unique developments aimed at reducing cardiovascular risks.